PT1690549E - Agente imunoterapêutico que é utilizado para o tratamento combinado de tuberculose juntamente com outros fármacos - Google Patents

Agente imunoterapêutico que é utilizado para o tratamento combinado de tuberculose juntamente com outros fármacos Download PDF

Info

Publication number
PT1690549E
PT1690549E PT04791401T PT04791401T PT1690549E PT 1690549 E PT1690549 E PT 1690549E PT 04791401 T PT04791401 T PT 04791401T PT 04791401 T PT04791401 T PT 04791401T PT 1690549 E PT1690549 E PT 1690549E
Authority
PT
Portugal
Prior art keywords
agent
combined treatment
immunotherapic
pharmaceuticals
tuberculosis
Prior art date
Application number
PT04791401T
Other languages
English (en)
Inventor
Pere Joan Cardona Iglesias
Isabel Amat Riera
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of PT1690549E publication Critical patent/PT1690549E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT04791401T 2003-10-31 2004-10-29 Agente imunoterapêutico que é utilizado para o tratamento combinado de tuberculose juntamente com outros fármacos PT1690549E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.

Publications (1)

Publication Number Publication Date
PT1690549E true PT1690549E (pt) 2009-07-20

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04791401T PT1690549E (pt) 2003-10-31 2004-10-29 Agente imunoterapêutico que é utilizado para o tratamento combinado de tuberculose juntamente com outros fármacos

Country Status (21)

Country Link
US (1) US8246944B2 (pt)
EP (1) EP1690549B1 (pt)
JP (1) JP4998988B2 (pt)
KR (1) KR101146469B1 (pt)
CN (1) CN100490894C (pt)
AT (1) ATE428442T1 (pt)
AU (1) AU2004285305B2 (pt)
BR (1) BRPI0415695B8 (pt)
CA (1) CA2543659C (pt)
DE (1) DE602004020663D1 (pt)
DK (1) DK1690549T3 (pt)
ES (2) ES2231037B1 (pt)
HK (1) HK1098362A1 (pt)
IL (1) IL175030A (pt)
MA (1) MA28121A1 (pt)
NZ (1) NZ546715A (pt)
PL (1) PL1690549T3 (pt)
PT (1) PT1690549E (pt)
RU (1) RU2341287C2 (pt)
WO (1) WO2005042013A1 (pt)
ZA (1) ZA200604234B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
CA2652475A1 (en) * 2006-05-12 2007-11-22 National University Corporation Hokkaido University Liposome having lipid membrane containing bacterial cell component
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
SI2661253T1 (sl) * 2011-01-04 2017-07-31 Archivel Farma, Sl Liposomska formulacija, ustrezna za zdravljenje ali preprečevanje tuberkuloze
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2013104943A1 (en) 2012-01-12 2013-07-18 Archivel Farma, S.L. Mtb-c vaccine against asthma
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
WO2023062066A1 (en) 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
CA2346218A1 (en) * 1998-10-08 2000-04-20 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
EP1351699A4 (en) * 2000-12-08 2006-07-05 Ying Dr Zhang METHOD FOR IMPROVED DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS
CA2433069C (en) * 2001-01-08 2010-03-30 Frederick D. Quinn Latent human tuberculosis model, diagnostic antigens, and methods of use
EP1379529A2 (en) * 2001-03-16 2004-01-14 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
BR0307262A (pt) 2002-01-29 2006-12-19 Bakulesh Mafatlal Khamar método de prover profilaxia para tuberculose em indivìduos hiv positivos
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
MA28121A1 (fr) 2006-08-01
US20070269501A1 (en) 2007-11-22
CA2543659A1 (en) 2005-05-12
BRPI0415695B8 (pt) 2021-05-25
BRPI0415695B1 (pt) 2019-09-10
BRPI0415695A8 (pt) 2019-01-15
DK1690549T3 (da) 2009-08-17
AU2004285305B2 (en) 2009-11-12
JP4998988B2 (ja) 2012-08-15
RU2341287C2 (ru) 2008-12-20
EP1690549A1 (en) 2006-08-16
ES2231037A1 (es) 2005-05-01
AU2004285305A1 (en) 2005-05-12
HK1098362A1 (en) 2007-07-20
KR101146469B1 (ko) 2012-05-21
ES2325835T3 (es) 2009-09-21
CA2543659C (en) 2012-04-17
CN100490894C (zh) 2009-05-27
BRPI0415695A (pt) 2006-12-26
US8246944B2 (en) 2012-08-21
CN1874785A (zh) 2006-12-06
DE602004020663D1 (de) 2009-05-28
RU2006118795A (ru) 2007-12-10
ES2231037B1 (es) 2005-12-16
JP2007509910A (ja) 2007-04-19
IL175030A (en) 2012-02-29
WO2005042013A1 (es) 2005-05-12
ATE428442T1 (de) 2009-05-15
ZA200604234B (en) 2007-11-28
EP1690549B1 (en) 2009-04-15
PL1690549T3 (pl) 2010-01-29
NZ546715A (en) 2008-05-30
KR20060126963A (ko) 2006-12-11
IL175030A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
HK1098362A1 (en) Immunotherapic agent which is used for the combined treatment of tuberculosis togetheir with other pharmaceuticals
TW200508214A (en) Novel compounds
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
PL373229A1 (en) Method and apparatus for the administration of co
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
HUP0401005A3 (en) Oxazolidinone and/or isoxazoline antibacterials, process for their preparation, their use and pharmaceutical compositions containing them
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE342053T1 (de) Formulierungen zur inhalation
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2002030405A3 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
MXPA04005552A (es) Analogos de vitamina d.
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
WO2003039457A3 (en) Anti-mycobacterial compounds
GB0128071D0 (en) Medicament
IL162857A0 (en) Oral vaccination